ValuEngine upgraded shares of Genocea Biosciences, Inc. (NASDAQ:GNCA) from a sell rating to a hold rating in a research report sent to investors on Monday, July 24th.
Several other brokerages also recently commented on GNCA. Needham & Company LLC upgraded Genocea Biosciences from a hold rating to a buy rating and set a $12.00 price target on the stock in a report on Monday, July 24th. Zacks Investment Research raised Genocea Biosciences from a hold rating to a buy rating and set a $6.75 price objective for the company in a research report on Wednesday, May 31st. One research analyst has rated the stock with a sell rating, one has issued a hold rating and five have given a buy rating to the stock. Genocea Biosciences presently has an average rating of Buy and an average target price of $16.52.
Genocea Biosciences (NASDAQ:GNCA) opened at 4.01 on Monday. The firm’s market capitalization is $114.78 million. Genocea Biosciences has a 52-week low of $3.28 and a 52-week high of $7.29. The stock’s 50 day moving average is $5.00 and its 200-day moving average is $5.50.
Genocea Biosciences (NASDAQ:GNCA) last announced its quarterly earnings results on Wednesday, August 9th. The biotechnology company reported ($0.54) EPS for the quarter, missing the consensus estimate of ($0.46) by $0.08. Equities analysts expect that Genocea Biosciences will post ($1.98) earnings per share for the current year.
In other Genocea Biosciences news, CFO Jonathan Poole sold 45,000 shares of Genocea Biosciences stock in a transaction on Monday, July 24th. The stock was sold at an average price of $6.00, for a total transaction of $270,000.00. Following the completion of the transaction, the chief financial officer now directly owns 84,247 shares of the company’s stock, valued at $505,482. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. 6.70% of the stock is currently owned by company insiders.
A number of hedge funds have recently made changes to their positions in the company. Ameriprise Financial Inc. raised its stake in shares of Genocea Biosciences by 34.1% in the first quarter. Ameriprise Financial Inc. now owns 19,933 shares of the biotechnology company’s stock worth $121,000 after buying an additional 5,068 shares during the last quarter. Keybank National Association OH purchased a new stake in shares of Genocea Biosciences during the first quarter worth approximately $147,000. JPMorgan Chase & Co. purchased a new stake in shares of Genocea Biosciences during the first quarter worth approximately $217,000. FMR LLC raised its stake in shares of Genocea Biosciences by 0.4% in the first quarter. FMR LLC now owns 4,274,804 shares of the biotechnology company’s stock worth $26,033,000 after buying an additional 18,574 shares during the last quarter. Finally, Segantii Capital Management Ltd purchased a new stake in shares of Genocea Biosciences during the first quarter worth approximately $160,000. Hedge funds and other institutional investors own 55.20% of the company’s stock.
About Genocea Biosciences
Genocea Biosciences, Inc, is harnessing the power of T cell immunity to develop vaccines and immunotherapies company. The Company uses its discovery platform, AnTigen Lead Acquisition System (ATLAS), to design vaccines and immunotherapies that act, in part, through T cell (or cellular) immune responses.
To view ValuEngine’s full report, visit ValuEngine’s official website.
What are top analysts saying about Genocea Biosciences Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Genocea Biosciences Inc. and related companies.